Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ValiRx plc ( (GB:VAL) ) has provided an announcement.
ValiRx PLC has extended its Evaluation Agreement with the University of Dundee for an additional year, focusing on the research of pro-senescence therapeutic candidates, which aim to halt cancer cell growth. The extension, supported by grants from Queen Mary University London and ValiRx, will allow further studies on the mechanism of action, crucial for potential in-licensing of the asset, and highlights ValiRx’s strategic collaboration to access required research expertise and facilities.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, aiming to accelerate the translation of innovative science into impactful medicines. The company provides a framework enabling rapid progression from scientific discovery to clinical development, utilizing expertise in research and drug development to guide novel drug candidates through optimized processes. ValiRx collaborates with various scientific, technical, and commercial experts to streamline the drug development process, and its lead candidates are licensed or partnered for further clinical development and commercialization.
YTD Price Performance: -0.64%
Average Trading Volume: 9,874,271
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.99M
For detailed information about VAL stock, go to TipRanks’ Stock Analysis page.
